BRPI0516515A - composições contendo lipase, protease e amilase para o tratamento da insuficiência pancreática - Google Patents

composições contendo lipase, protease e amilase para o tratamento da insuficiência pancreática

Info

Publication number
BRPI0516515A
BRPI0516515A BRPI0516515-6A BRPI0516515A BRPI0516515A BR PI0516515 A BRPI0516515 A BR PI0516515A BR PI0516515 A BRPI0516515 A BR PI0516515A BR PI0516515 A BRPI0516515 A BR PI0516515A
Authority
BR
Brazil
Prior art keywords
pancreatic insufficiency
protease
treatment
lipase
compositions
Prior art date
Application number
BRPI0516515-6A
Other languages
English (en)
Inventor
Alexey L Margolin
Bhami C Shenoy
Frederick T Murray
Original Assignee
Altus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Pharmaceuticals Inc filed Critical Altus Pharmaceuticals Inc
Publication of BRPI0516515A publication Critical patent/BRPI0516515A/pt
Publication of BRPI0516515B1 publication Critical patent/BRPI0516515B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIçõES CONTENDO LIPASE, PROTEASE E AMILASE PARA O TRATAMENTO DA INSUFICIêNCIA PANCREáTICA. A presente invenção refere-se às composições para o tratamento de condições, incluindo a insuficiência pancreática. As composições da presente invenção compreendem lipase, protease e amilase em uma relação particular que fornece resultados benéficos em pacientes, tais como aqueles afligidos com insuficiência pancreática. Esta invenção refere-se aos métodos que utilizam tais composições para o tratamento de insuficiência pancreática.
BRPI0516515-6A 2004-10-14 2005-10-14 Composição compreendendo lipase, protease e amilase e uso da mesma BRPI0516515B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61876404P 2004-10-14 2004-10-14
US60/618,764 2004-10-14
PCT/US2005/036802 WO2006044529A1 (en) 2004-10-14 2005-10-14 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency

Publications (2)

Publication Number Publication Date
BRPI0516515A true BRPI0516515A (pt) 2008-09-16
BRPI0516515B1 BRPI0516515B1 (pt) 2018-05-29

Family

ID=35840531

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516515-6A BRPI0516515B1 (pt) 2004-10-14 2005-10-14 Composição compreendendo lipase, protease e amilase e uso da mesma

Country Status (23)

Country Link
US (1) US7718169B2 (pt)
EP (2) EP1809320B1 (pt)
JP (1) JP4908420B2 (pt)
KR (1) KR101333664B1 (pt)
CN (1) CN101068565B (pt)
AT (1) ATE474592T1 (pt)
AU (1) AU2005295754B2 (pt)
BR (1) BRPI0516515B1 (pt)
CA (1) CA2584069C (pt)
CY (2) CY1110838T1 (pt)
DE (1) DE602005022471D1 (pt)
DK (2) DK1809320T3 (pt)
ES (2) ES2614157T3 (pt)
HR (1) HRP20161684T1 (pt)
HU (1) HUE031245T2 (pt)
LT (1) LT2198880T (pt)
MX (1) MX2007004534A (pt)
PL (2) PL2198880T3 (pt)
PT (2) PT2198880T (pt)
RU (1) RU2385736C2 (pt)
SI (2) SI1809320T1 (pt)
UA (1) UA91521C2 (pt)
WO (1) WO2006044529A1 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
ES2314646T3 (es) 2004-03-22 2009-03-16 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
WO2006002453A2 (en) * 2004-07-07 2006-01-12 Biodevelops Pharma Entwicklung Gmbh Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US8273348B2 (en) 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
AU2008218595B2 (en) 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
RU2445952C2 (ru) * 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) * 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2328609A1 (en) * 2008-08-26 2011-06-08 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
WO2010037695A1 (en) * 2008-09-30 2010-04-08 Dsm Ip Assets B.V. Enzyme composition and application thereof in the treatment of pancreatic insufficiency
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
JP2012514604A (ja) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
CA3050530A1 (en) * 2009-01-06 2010-07-15 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010085975A1 (de) * 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2010130622A1 (en) * 2009-05-11 2010-11-18 Dsm Ip Assets B.V. Enzyme composition for the treatment of prancreatic insufficiency
PL2295039T5 (pl) 2009-08-28 2023-02-27 Nordmark Pharma Gmbh Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
AU2016216662B2 (en) * 2009-09-17 2017-09-07 Allergan Therapeutics LLC Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US20110135728A1 (en) * 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
RU2429291C1 (ru) * 2009-12-28 2011-09-20 Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России) Пищеварительное средство на основе ферментов микробного происхождения
JP2011162491A (ja) * 2010-02-10 2011-08-25 Ezaki Glico Co Ltd 乾燥麹抽出物及びこれを用いた口腔用組成物
SE535296C2 (sv) 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
FR2966734B1 (fr) 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
MX351014B (es) 2011-08-08 2017-09-28 Aptalis Pharma Ltd Metodo para la prueba de disolucion de composiciones solidas que contienen enzimas digestivas.
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
NZ629943A (en) 2012-02-17 2016-06-24 Alcresta Inc Methods, compositions, and devices for supplying dietary fatty acid needs
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2013318686B2 (en) * 2012-09-19 2017-11-30 Grespo Ab Compositions for improvement of brain function
KR20160055721A (ko) 2013-03-15 2016-05-18 앨러간 파마슈티컬스 인터내셔널 리미티드 장용 투여에 적합한 영양소 및 소화 효소를 함유하는 조성물
US9861681B2 (en) 2013-04-18 2018-01-09 The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases Therapeutic compositions for neutralizing type I interferons, and methods of use
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US20160152968A1 (en) 2013-07-22 2016-06-02 Aptalis Pharma Ltd. High potency pancreatin pharmaceutical compositions
CN106163544A (zh) 2013-08-09 2016-11-23 阿勒根制药国际有限公司 适于经肠施用的消化酶组合物
CN106659773A (zh) 2013-11-05 2017-05-10 阿勒根制药国际有限公司 高效的胰酶药物组合物
JP2014193909A (ja) * 2014-06-04 2014-10-09 Nordmark Arzneimittel Gmbh & Co Kg 医薬調製物
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
DK3267197T3 (da) * 2015-03-02 2020-10-12 Toray Industries Fremgangsmåde og kit til detektionen af pankreatisk dysfunktion
DE102015114859A1 (de) * 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
DE102017104472A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
FR3079146B1 (fr) 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
US11547745B1 (en) 2018-08-23 2023-01-10 Vets Plus, Inc. Compositions and methods for treating pancreatic enzyme deficiencies in mammals
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.
US20230138700A1 (en) * 2020-03-30 2023-05-04 Jai WALL Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4408990A2 (en) * 2021-09-30 2024-08-07 Anagram Therapeutics, Inc. Engineered lipase enzymes, manufacture and use thereof
AU2024336654A1 (en) 2023-09-05 2026-04-16 The Regents Of The University Of California Enzymes for oxidizing beta-hydroxybutyrate (bhb), test strips, and sensors of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5017559B2 (pt) 1972-09-20 1975-06-21
JPS5428820Y2 (pt) * 1974-06-14 1979-09-14
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4659667A (en) * 1985-02-26 1987-04-21 Miles Laboratories, Inc. Process to recover crystalline enzymes and crystalline enzymes produced thereby
DK154572C (da) * 1985-08-07 1989-04-24 Novo Industri As Enzymatisk detergentadditiv, detergent og fremgangsmaade til vask af tekstiler
JP3079276B2 (ja) * 1988-02-28 2000-08-21 天野製薬株式会社 組換え体ｄｎａ、それを含むシュードモナス属菌及びそれを用いたリパーゼの製造法
DE3808695A1 (de) * 1988-03-16 1989-10-05 Henkel Kgaa Fluessiges waschmittel
EP0387945B1 (en) 1989-03-08 1993-11-03 Simon Lodewijk Scharpé A composition for the treatment of exocrine insufficiency of the pancreas, and the use of said composition
EP0506791B1 (en) 1989-12-21 1993-09-08 Novo Nordisk A/S Enzyme containing preparation and detergent containing such preparation
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
DE69133258T2 (de) 1990-08-03 2004-03-18 Vertex Pharmaceuticals Inc., Cambridge Verwendung von vernetzten kristallen als neuem verfahren zur immobilisierung von enzymen
US5892013A (en) * 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
WO1993000924A1 (de) * 1991-07-01 1993-01-21 Basf Aktiengesellschaft Verwendung von lipasen zur herstellung von arzneimitteln
JPH07504561A (ja) * 1991-12-20 1995-05-25 ノボ　ノルディスク　アクティーゼルスカブ リパーゼの製造のための方法
JPH08503691A (ja) * 1992-06-30 1996-04-23 コーテックス リミテッド 下痢の治療における酵素、特にブロメラインの使用
DK154292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Nyt enzym
DK39693D0 (da) * 1993-04-02 1993-04-02 Novo Nordisk As Enzym
GB9403344D0 (en) * 1994-02-22 1994-04-13 Cortecs Ltd Medical application of bromelain
DE4408152A1 (de) * 1994-03-11 1995-09-14 Studiengesellschaft Kohle Mbh Immobilisierte Lipasen in hydrophoben Sol-Gel-Materialien
WO1995030744A2 (en) * 1994-05-04 1995-11-16 Genencor International Inc. Lipases with improved surfactant resistance
DE69634248T2 (de) 1995-05-31 2006-01-12 Medzyme N.V. Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
WO1999012959A1 (en) 1997-09-05 1999-03-18 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6156552A (en) * 1998-02-18 2000-12-05 Novo Nordisk A/S Lipase variants
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.

Also Published As

Publication number Publication date
SI1809320T1 (sl) 2010-11-30
ES2352086T3 (es) 2011-02-15
EP1809320B1 (en) 2010-07-21
US7718169B2 (en) 2010-05-18
CY1118597T1 (el) 2017-07-12
CN101068565A (zh) 2007-11-07
RU2007117728A (ru) 2008-11-20
HK1109068A1 (en) 2008-05-30
LT2198880T (lt) 2017-02-27
AU2005295754A2 (en) 2010-09-02
PT1809320E (pt) 2010-10-25
EP2198880B1 (en) 2016-11-23
KR20070074622A (ko) 2007-07-12
WO2006044529A1 (en) 2006-04-27
PL1809320T3 (pl) 2011-11-30
UA91521C2 (ru) 2010-08-10
AU2005295754A1 (en) 2006-04-27
JP2008516965A (ja) 2008-05-22
DE602005022471D1 (de) 2010-09-02
ATE474592T1 (de) 2010-08-15
CA2584069C (en) 2017-02-07
JP4908420B2 (ja) 2012-04-04
US20060121017A1 (en) 2006-06-08
BRPI0516515B1 (pt) 2018-05-29
RU2385736C2 (ru) 2010-04-10
CA2584069A1 (en) 2006-04-27
EP2198880A1 (en) 2010-06-23
SI2198880T1 (sl) 2017-02-28
CY1110838T1 (el) 2015-06-10
AU2005295754B2 (en) 2010-09-09
DK1809320T3 (da) 2010-11-15
EP1809320A1 (en) 2007-07-25
DK2198880T3 (en) 2017-01-23
CN101068565B (zh) 2010-11-17
PL2198880T3 (pl) 2017-04-28
PT2198880T (pt) 2017-01-04
HRP20161684T1 (hr) 2017-02-24
MX2007004534A (es) 2007-11-08
ES2614157T3 (es) 2017-05-29
HUE031245T2 (en) 2017-06-28
KR101333664B1 (ko) 2013-11-28

Similar Documents

Publication Publication Date Title
UA91521C2 (ru) Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
BR112012027765A2 (pt) métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
CR20140422A (es) Composiciones de enzima digestiva estable
MX2010009456A (es) Composicion detergente que comprende lipasa.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX2012006628A (es) Microorganismos probioticos como agentes activos para mejorar el brillo de la piel.
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
BR112022001054A2 (pt) Inibidores enzimáticos
BR112012005837A8 (pt) Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática
BRPI0922653B8 (pt) uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
BRPI0510697A (pt) gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
BR112022022985A2 (pt) Métodos e composições para induzir adipogênese marrom
ECSP088764A (es) Métodos para tratar trastornos cognitivos y otros afines
BR112014012966A2 (pt) método para o controle da proliferação de pseudomonas; e uso de um agente de desinfecção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CYSTIC FIBROSIS FOUNDATION THERAPEUTICS , INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ELI LILLY AND COMPANY (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/05/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2535 DE 06-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.